CCL20 and asthma: Twenty-four hours after the last OVA challenge, we performed BAL analyses and confirmed that the anti-CCL20 antibody reduced eosinophil percentage of total from 17% to 2% and significantly decreased eosinophil counts in the OVA-induced asthma mouse model (P<0.01, Fig 3A).